GlassScriptPhysician profile
Anthony R Cesario
NPI 1992938641
$2,563.46
in general payments reported to CMS, 2019-2025
13 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.45 · 2022: $362 · 2023: $750 · 2024: $1,080 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $562.40 | 2024-2025 | Brixadi |
| Alkermes, INC. | $390.45 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $344.92 | 2022-2024 | Sublocade |
| Almatica Pharma LLC | $295.45 | 2021-2024 | Loreev Xr, Sertraline Hcl, Gralise |
| Corium, LLC | $246.86 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $222.07 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $135.81 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.89 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $104.44 | 2023-2025 | Invega Sustenna |
| Orexo US, INC. | $60.92 | 2021-2024 | Zubsolv |
| Lundbeck LLC | $39.46 | 2022-2023 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $37.73 | 2022-2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $18.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cesario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.